서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 61 to 120 of 194

Issue DateTitle / Author(s) / CitationFileAltmetrics
2014-11
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
DOI
2014-11
A Phase II Study of Ifosfamide, Methotrexate, Etoposide, and Prednisolone for Previously Untreated Stage I/II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Multicenter Trial of the Korean Cancer Study Group
DOI
2014-12
Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas
DOI
2014-12
Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score
DOI
2014-12
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer

Sim, Sung Hoon; Keam, Bhumsuk; Kim, Dong-Wan; Kim, Tae Min; Lee, Se-Hoon; Chung, Doo Hyun; Heo, Dae Seog

Journal of Cancer Research and Clinical Oncology, Vol.140 No.12, pp.2135-2142

DOI
2015-01
In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer
2015-01
An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients
DOI
2015-03
Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL)
DOI
2015-04
The impact of molecularly targeted treatment on direct medical costs in patients with advanced non-small cell lung cancer

Lee, June-Koo; Kim, Dong-Wan; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Young-Joo; Heo, Dae Seog

Cancer Research and Treatment, Vol.47 No.2, pp.182-188

view fileDOI
2015-05
Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer

Song, Ahnah; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Keam, Bhumsuk; Lee, Se-Hoon; Heo, Dae Seog

Clinical Cancer Research, Vol.21 No.10, pp.2379-2387

DOI
2015-06
Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, Sung Hoon; Kim, Yu Jung; Kim, Se Hyun; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog; Lee, Jong Seok

Journal of Cancer Research and Clinical Oncology, Vol.141 No.6, pp.1073-1081

DOI
2015-06
MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma
DOI
2015-07
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
DOI
2015-08
Total lesion glycolysis in positron emission tomography can predict gefitinib outcomes in non-small-cell lung cancer with activating EGFR mutation
DOI
2015-09
Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma
DOI
2015-09
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
DOI
2015-10
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
view fileDOI
2015-10
Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer

Lee, Yun-Gyoo; Lee, Eunyoung; Kim, Inho; Lee, Keun-Wook; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog

Cancer Research and Treatment, Vol.47 No.4, pp.670-675

view fileDOI
2015-10
Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute

Choi, Younak; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog

Cancer Research and Treatment, Vol.47 No.4, pp.555-563

view fileDOI
2015-10
A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer
DOI
2015-11
Targeting stemness is an effective strategy to control EML4-ALK(+) non-small cell lung cancer cells
view fileDOI
2015-11
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure

Cho, Kyoung Min; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Kim, Dong-Wan; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.30 No.6, pp.891-898

view fileDOI
2015-12
MET amplification, protein expression, and mutations in pulmonary adenocarcinoma
DOI
2015-12
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
DOI
2016-01
Gefitinib-induced interstitial lung disease in korean lung cancer patients
view fileDOI
2016-01
Reduced dose intensities of doxorubicin in elderly patients with DLBCL in rituximab era

Ha, Hyerim; Keam, Bhumsuk; Kim, Tae Min; Jeon, Yoon Kyung; Lee, Se-Hoon; Kim, Dong-Wan; Kim, Chul Woo; Heo, Dae Seog

Cancer Research and Treatment, Vol.48 No.1, pp.304-311

view fileDOI
2016-02
Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study
view fileDOI
2016-02
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
view fileDOI
2016-02
Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience
DOI
2016-03
Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer
DOI
2016-03
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors
view fileDOI
2016-03
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 alpha and STAT3
DOI
2016-03
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma
view fileDOI
2016-03
Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors
DOI
2016-04
Identification of genomic mutations associated with clinical outcomes of induction chemotherapy in patients with head and neck squamous cell carcinoma
DOI
2016-04
VEGF and Ki-67 overexpression in predicting poor overall survival in adenoid cystic carcinoma
view fileDOI
2016-05
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: A role in organ preservation
view fileDOI
2016-05
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
DOI
2016-06
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
DOI
2016-07
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
DOI
2016-07
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer
DOI
2016-07
The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell carcinoma: A meta-analysis
view fileDOI
2016-08
An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone

Nam, Soo Jeong; Kim, Sehui; Paik, Jin Ho; Kim, Tae Min; Heo, Dae Seog; Kim, Chul Woo; Jeon, Yoon Kyung

Leukemia and Lymphoma, Vol.57 No.8, pp.1956-1960

DOI
2016-10
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
view fileDOI
2016-10
Immune reconstitution inflammatory syndrome versus non-immune reconstitution inflammatory syndrome lymphoma in HIV patients on antiretroviral therapy
DOI
2016-11
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations

Park, Sehhoon; Park, Seongyeol; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Kim, Young Whan; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.31 No.6, pp.1140-1149

view fileDOI
2017-01
Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications
DOI
2017-03
Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non-Small Cell Lung Cancer
DOI
2017-03
Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles
DOI
2017-04
MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics
DOI
2017-05
Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy
DOI
2017-05
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
DOI
2017-05
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Park, Sehhoon; Kim, Ji-Yeon; Lee, Se-Hoon; Suh, Beomseok; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.32 No.3, pp.514-522

view fileDOI
2017-06
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
view fileDOI
2017-08
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
DOI
2017-09
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
DOI
2017-10
Korean Cancer Patients' Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
view fileDOI
2017-10
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
DOI
2017-11
Diagnosis of secondary peripheral neurolymphomatosis: A multi-center experience
DOI
2017-11
The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
view fileDOI
1 2 3 4